Evaluation of the hypothetical risk of sudden cardiac death in obstructive HCM patients treated with mavacamten using the HCM Risk-SCD score

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Rui Miguel Esculudes Dos Santos Ferrao Gomes

Centro Universitario da Unidade Local de Saude de Lisboa Ocidental, Lisboa (Portugal)

6 More presentations in this session

Presentation thumbnail

Artificial intelligence-enabled electrocardiography to predict left ventricular ejection fraction decline in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten

Doctor J. Choi (Seongnam, KR)

Presentation thumbnail

Comparison of transcoronary ablation of septal hypertrophy (TASH) and Mavacamten treatment in patients with obstructive hypertrophic cardiomyopathy: a single-center study

Doctor J. Koelemen (Heidelberg, DE)

Presentation thumbnail

No increase in arrhythmia burden following aficamten treatment in obstructive hypertrophic cardiomyopathy: extended ambulatory electrocardiogram analysis from FOREST-HCM

Doctor E. Rowin (Burlington, US)

Presentation thumbnail

Real-world individual patient-level analysis for mavacamten in obstructive hypertrophic cardiomyopathy: multi-domain response, safety and cyp2c19 genotype effects

Doctor P. Zwetsloot (Rotterdam, NL)

Presentation thumbnail

The effect of mavacamten therapy on the risk of sudden cardiac death among patients with hypertrophic obstructive cardiomyopathy

Doctor F. Banfi-Bacsardi (Budapest, HU)

Access the full session

Session thumbnail

Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources